Related Experiment Video

Updated: Aug 19, 2026

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

Is plasma cardiotrophin-1 a marker of hypertensive heart disease?

Begoña López1, Arantxa González, Juan J Lasarte

  • 1Area of Cardiovascular Pathophysiology, Centre for Applied Medical Research, School of Medicine, University of Navarra, Navarra, Spain.

Journal of Hypertension
|February 18, 2005
PubMed

Insights

Plasma cardiotrophin-1 (CT-1) is elevated in hypertensive patients, particularly those with left ventricular hypertrophy (LVH). CT-1 levels correlate with LVH, suggesting its potential as a biomarker for hypertensive heart disease screening.

Area of Science:

  • Cardiovascular Medicine
  • Biomarkers
  • Hypertension Research

Background:

  • Essential hypertension is a leading cause of cardiovascular disease.
  • Left ventricular hypertrophy (LVH) is a key indicator of hypertensive heart disease.
  • Cardiotrophin-1 (CT-1) is a cytokine implicated in cardiac remodeling.

Purpose of the Study:

  • To investigate the association between plasma CT-1 levels and LVH in patients with essential hypertension.
  • To determine if CT-1 can serve as a biomarker for hypertensive heart disease.

Main Methods:

  • A novel enzyme-linked immunosorbent assay was developed to measure plasma CT-1.
  • Plasma CT-1 was measured in 31 normotensive subjects and 111 hypertensive patients (with and without LVH).
  • Echocardiography was used to assess left ventricular hypertrophy.

Main Results:

  • Plasma CT-1 levels were significantly higher in hypertensive patients compared to normotensive individuals (P < 0.001).
  • Hypertensive patients with LVH exhibited higher CT-1 levels than those without LVH (P < 0.001).
  • A direct correlation was observed between plasma CT-1 and left ventricular mass index (r = 0.319, P < 0.001).

Conclusions:

  • Plasma CT-1 concentration is associated with LVH in essential hypertension.
  • CT-1 may represent a valuable, non-invasive biomarker for the initial screening and diagnosis of hypertensive heart disease.
Abstract

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...